Research programme: therapeutic antiviral vaccines - Abivax/CIGB

Drug Profile

Research programme: therapeutic antiviral vaccines - Abivax/CIGB

Alternative Names: ABX-318; anti-HPV vaccine - Abivax/CIGB

Latest Information Update: 21 Feb 2014

Price : $50

At a glance

  • Originator BC Cancer Agency; Wittycell
  • Developer Abivax; Cuban Center for Genetic Engineering and Biotechnology; Wittycell
  • Class Papillomavirus vaccines
  • Mechanism of Action Immunostimulants; Natural killer cell receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cervical cancer; Cervical dysplasia; Human papillomavirus infections

Most Recent Events

  • 13 Feb 2014 Preclinical trials in Cervical dysplasia in France
  • 13 Feb 2014 Preclinical trials in Human papillomavirus infections in France
  • 13 Feb 2014 Preclinical trials in Cervical cancer (prevention) in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top